Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
13F holders, Q3 2024
Institutional positions in Cero Therapeutics Holdings, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +4 vs. Q2 2024
- Shares held
- 3.44M
- +1.70M (+97.3%) vs. Q2 2024
- Total value
- $320.0K
- −$177.7K (−35.7%) vs. Q2 2024
- New holders
- 5
- 6 more added
- Sold out
- 1
- 0 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CERO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 11 | $798.7K |
| Q2 2025 | 8 | $2.38M |
| Q1 2025 | 15 | $527.7K |
| Q4 2024 | 21 | $800.3K |
| Q3 2024 | 18 | $320.0K |
| Q2 2024 | 15 | $557.1K |
| Q1 2024 | 9 | $4.85M |
| Q4 2023 | 10 | $7.49M |
| Q3 2023 | 10 | $7.33M |
| Q2 2023 | 13 | $10.6M |
| Q1 2023 | 17 | $12.5M |
| Q4 2022 | 46 | $101.1M |
| Q3 2022 | 66 | $153.0M |
| Q2 2022 | 54 | $144.5M |
| Q1 2022 | 45 | $137.2M |
| Q4 2021 | 36 | $104.2M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Cero Therapeutics Holdings, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 1,444,296 | $134.8K | 0.05% | 00.0% | Unchanged |
| Avantax Planning Partners, Inc. | 1,361,130 | $127.0K | 0.00% | +1,281,130+1,601.4% | Added |
| Geode Capital Management, LLC | 157,445 | $14.7K | 0.00% | +109,303+227.0% | Added |
| Selkirk Management LLC | 121,040 | $11.3K | 0.00% | +121,040 | New |
| HRT Financial LP | 79,562 | $7.00K | 0.00% | +67,627+566.6% | Added |
| Fifth Lane Capital, LP | 76,593 | $6.89K | 0.02% | 00.0% | Unchanged |
| Jane Street Group, LLC | 56,998 | $5.32K | 0.00% | +24,961+77.9% | Added |
| XTX Topco Ltd | 56,532 | $5.27K | 0.00% | +56,532 | New |
| FNY Investment Advisers, LLC | 26,250 | $2.00K | 0.00% | +21,000+400.0% | Added |
| StoneX Group Inc. | 16,600 | $1.55K | 0.00% | +16,600 | New |
| CI Private Wealth, LLC | 14,999 | $1.40K | 0.00% | 00.0% | Unchanged |
| Birchview Capital, LP | 12,972 | $1.21K | 0.00% | 00.0% | Unchanged |
| Jump Financial, LLC | 11,948 | $1.11K | 0.00% | +11,948 | New |
| Tower Research Capital LLC (TRC) | 4,965 | $462 | 0.00% | +4,965 | New |
| Advisor Group Holdings, Inc. | 400 | $36 | 0.00% | 00.0% | Unchanged |
| Pineridge Advisors LLC | 300 | $28 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 232 | $22 | 0.00% | +164+241.2% | Added |
| JPMorgan Chase & Co | 2 | $0 | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −18,096−100.0% | Sold out |
| Arena Investors LP | – | – | – | – | Not filed |